Royalty payment

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
화요일, 4월 30, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Education, PFS, Abbreviated New Drug Application, European Patent Office, Experiment, Breast, NET, ASCO, RCC, Associate, Translation, European Medicines Agency, Hearing, PIN, Drug development, European Patent Convention, Metastasis, Conference, Liver disease, ADC, Stada Arzneimittel, Tablet, Baylor College of Medicine, Distinguishing, Therapy, NHT, Calendar, BIRC, Huntsman Cancer Institute, OS, Dean (education), Docetaxel, PKMYT1, Checkmate, Prostate cancer, ITT, EPO, USP1, University, PARP, Immunotherapy, Superior, PLK4, Patent, Royalty payment, Patient, Society, Acquisition, Translational research, Neoplasm, Share repurchase, Annual general meeting, Baylor University

Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.

Key Points: 
  • Exelixis’ 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2024, Exelixis earned $39.6 million in royalty revenues.
  • In January, Exelixis announced the appointments of Mary C. Beckerle, Ph.D., and S. Gail Eckhardt, M.D., to the Exelixis Board of Directors, effective January 5, 2024.
  • Exelixis management will discuss the company’s financial results for the first quarter of 2024 and provide a general business update during a conference call beginning at 5:00 p.m.

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Retrieved on: 
수요일, 4월 10, 2024
Use, BioLite, Ophthalmology, Polysaccharide, Pancreatic cancer, License, Dietary supplement, Partnership, IND, CNS, Non-small-cell lung cancer, CDMO, Knowledge, Investigational New Drug, Therapy, Royalty payment, Field, Edible, Myelodysplastic syndrome, Triple-negative breast cancer, MDS, Ergosterol, NSCLC, TNBC, US FDA, Pharmaceutical industry

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • [1]
    "We are thrilled to announce that the term sheet for a potential groundbreaking licensing deal with OncoX has been successfully executed.
  • This licensing deal marks a significant milestone for ABVC and OncoX, affirming their commitment to excellence and shared vision for the future.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

Genel Energy PLC: Report on payments to governments

Retrieved on: 
수요일, 4월 10, 2024
Regulation, Disclosure, DA-88, Royalty payment, Prospection, Financial Conduct Authority, Government, Genel Energy

This report sets out details of the payments made to governments by Genel Energy plc and its subsidiary undertakings (‘Genel’) for the year ended 31 December 2023 as required under the Disclosure and Transparency Rules of the UK Financial Conduct Authority (the ‘DTRs’) and in accordance with our interpretation of the Industry Guidance issued for the UK’s Report on Payments to Governments Regulations 2014, as amended in December 2015 (‘the Regulations’).

Key Points: 
  • This report sets out details of the payments made to governments by Genel Energy plc and its subsidiary undertakings (‘Genel’) for the year ended 31 December 2023 as required under the Disclosure and Transparency Rules of the UK Financial Conduct Authority (the ‘DTRs’) and in accordance with our interpretation of the Industry Guidance issued for the UK’s Report on Payments to Governments Regulations 2014, as amended in December 2015 (‘the Regulations’).
  • Production entitlements are the host government’s share of production during the reporting period from projects operated by Genel.
  • Production entitlements from projects that are not operated by Genel are not covered by this report.
  • Total payments below £86,000 made to a government are excluded from this report as permitted under the Regulations.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
화요일, 2월 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Royalty payment, Conference, Liver disease, Calendar, Breast, Immunotherapy, RCC, PIN, ASCO, NHT, Progression-free survival, Safety, FDA, PLK4, ADC, ITT, PKMYT1, Associate, University, Baylor University, PARP, USP1, Society, Neck, Science, Acquisition, Biology, Superior, Huntsman Cancer Institute, Dean (education), Metastasis, PFS, Translational research, Drug development, Distinguishing, Head, Food, NET, Baylor College of Medicine, Cancer, Share repurchase, BIRC, OS, SCCHN, Neoplasm, Congress, National Cancer Institute, Abbreviated New Drug Application, Research, Docetaxel, Translation, Prostate cancer, Therapy, ESMO, Education, Experiment, Checkmate, Pharmaceutical industry

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

Cielo Announces Extension of Deadline to Pay Royalties

Retrieved on: 
금요일, 1월 12, 2024
CMC, Exercise, Royalty payment

CALGARY, Alberta, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a waste-to-fuel environmental technology company, announces today that it has extended the date by which it is required to pay royalties (the “Royalties”) to July 3, 2024.

Key Points: 
  • CALGARY, Alberta, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a waste-to-fuel environmental technology company, announces today that it has extended the date by which it is required to pay royalties (the “Royalties”) to July 3, 2024.
  • In 2018, the Company had undertaken an early warrant exercise incentive program, issuing a $0.0875 fixed rate royalty for each of the 10,162,500 warrants that were exercised.
  • The deadline to pay the Royalties was originally July 3, 2020, which was extended in July 2020 and again in July 2022, requiring repayment in January 2024.
  • The Company is pleased to have received the required approval from the holders of the Royalties for the extension to July 2024, allowing the Company to focus its resources on the further development of its first commercial waste-to-fuel project in Carseland, Alberta.

Euro Manganese Reports Fourth Quarter and Year-End 2023 Financial Results and Project Developments

Retrieved on: 
목요일, 12월 14, 2023
FEED, Government, CapeNature, Mineral, Municipality, Financial statement, IRR, Private sector, Village, Memorandum of understanding, Royalty payment, Demonstration plant, Economics, Agreement, Collection, OMRF, EMN, Manganese, MMC, Documentation, Overalls, Commission, EPCM, Mining, Grand Conseil, Feasibility study, Civil service commission, Calendar, NPV, Engineering, Demonstration, Planning permission, European Commission, ASX, Partner, Acquisition, BK, Growth, Chvaletice, MSP, Renewable energy

VANCOUVER, British Columbia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") is pleased to announce key developments during the fourth fiscal quarter 2023 and to date.

Key Points: 
  • VANCOUVER, British Columbia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (the "Company" or "EMN") is pleased to announce key developments during the fourth fiscal quarter 2023 and to date.
  • The Company has now filed its September 30, 2023 year-end Financial Statements, Management’s Discussion and Analysis, and other financial reports.
  • US$100 million non-dilutive funding package announced to advance development of the Chvaletice Manganese Project (the "Project"); US$20 million received on closing.
  • The Chvaletice Project received high-level inter-governmental support during the fourth calendar quarter by being named as a project under the Minerals Security Partnership.

Sound Royalties Accelerates Company Growth by Creating Business Relationship with Music Banking Veteran David Innes

Retrieved on: 
수요일, 11월 8, 2023
GoDigital Media Group, Innes, NARAS, Senior, Growth, Music, Grammy Awards, City National Bank, Royalty payment

MIAMI, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sound Royalties , a subsidiary of GoDigital Media Group and the music industry’s leading finance firm for nearly a decade, is continuing to accelerate its growth strategies by announcing a new working relationship with David Innes.

Key Points: 
  • MIAMI, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sound Royalties , a subsidiary of GoDigital Media Group and the music industry’s leading finance firm for nearly a decade, is continuing to accelerate its growth strategies by announcing a new working relationship with David Innes.
  • The entertainment banking veteran will support Sound Royalties by amplifying its networking reach among music creatives and expanding its new business pipeline.
  • “Sound Royalties continues to experience strong growth, and with the current prime rate at 8.5%, our fixed fee and fixed term funding has become even more appealing to the marketplace.
  • His new venture, On the Money Entertainment Advisory and Consulting, will work with Sound Royalties to align music creatives with the right resources to support their projects.

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

Retrieved on: 
목요일, 8월 31, 2023
Exercise, BofA Securities, Code, NASH, SEC Rule 144A, Equity carve-out, Public company, Transaction, Loi autorisant le divorce en France, Commercial code, SGLT2, Person, Qatar Investment Authority, Sale, Royalty payment, NPV, Patient, European, Fatty liver disease, ISIN, United Kingdom, European Investment Bank, Phase, EIB, III, Pharmaceutical industry, Security (finance), Life insurance, Cryptocurrency, Bank, Real estate, Music, EU, Euronext Paris

As a result, the Company will not have sufficient net working capital over the next twelve months after the Capital Increase and the issuance of the Royalty Certificates.

Key Points: 
  • As a result, the Company will not have sufficient net working capital over the next twelve months after the Capital Increase and the issuance of the Royalty Certificates.
  • After the Capital Increase, Sofinnova Partner will hold 9.8% of the share capital of the Company, on a non-diluted basis.
  • After the Capital Increase, Yiheng Capital will hold 7.4% of the share capital of the Company, on a non-diluted basis.
  • The Royalty Certificates will not be listed on any stock exchange and will not be assigned an ISIN.

Osisko Announces Royalty Transaction With Hot Chili on the Costa Fuego Copper-Gold Project in Chile

Retrieved on: 
수요일, 6월 28, 2023
Hot Chili, Costa, NSR, Pan-American Highway (South America), MRE, PFS, NYSE, Osisko Gold Royalties, PEA, Gold, Royalty payment, Seawater, National instrument, Mining, Water, Project, National Instrument 43-101, News, Mineral Resources Limited, Copper, Music, Molybdenum, Atacama Desert, Productora de Software

MONTREAL, June 28, 2023 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (“Osisko”) (OR: TSX & NYSE) is pleased to announce that it has entered into a binding agreement to acquire a 1.0% copper net smelter return (“NSR”) royalty and a 3.0% gold NSR royalty (the “Royalties”) from Hot Chili Limited (“Hot Chili”) covering Hot Chili’s Costa Fuego Copper-Gold Project (“Costa Fuego” or the “Project”) in Chile, for total cash consideration of US$15.0 million.

Key Points: 
  • MONTREAL, June 28, 2023 (GLOBE NEWSWIRE) -- Osisko Gold Royalties Ltd (“Osisko”) (OR: TSX & NYSE) is pleased to announce that it has entered into a binding agreement to acquire a 1.0% copper net smelter return (“NSR”) royalty and a 3.0% gold NSR royalty (the “Royalties”) from Hot Chili Limited (“Hot Chili”) covering Hot Chili’s Costa Fuego Copper-Gold Project (“Costa Fuego” or the “Project”) in Chile, for total cash consideration of US$15.0 million.
  • Osisko has granted Hot Chili an option to buy down a portion of the royalty, which can only occur upon change of control and exercisable until the fourth anniversary of the transaction close.
  • Should Hot Chili’s ownership of these properties increase, the royalty will thereafter apply to the increased ownership level.
  • Productora is held in a joint venture, presently 80% owned by Hot Chili and Cortadera is 100% owned by Hot Chili.

Royal Gold Announces Commitment to Acquire Gold/Platinum/Palladium and Copper/Nickel Royalties on Producing Serrote and Santa Rita Mines in Brazil

Retrieved on: 
월요일, 6월 12, 2023
Mining, Minerals, Natural Resources, Société Générale, Financial Conduct Authority, Competence, De Contas River, Royalty payment, Acquisition, Investment, ESG, Volkswagen Group, CapeNature, Maintenance, London Stock Exchange, Life, Platinum, Water supply, Powerco, Nickel, Citigroup, Growth, Cobalt, Safety, LLP, SLR Consulting, ING, History, Carbon, PEA, Documentation, GEO, Water, FCA, Caboclo, Letter, CPR, Glencore, Royal Gold, GEOS, Indication (medicine), GHG, Palladium, Sale, London, United Kingdom, Copper, ACG, AISC, Music, Bank, Cryptocurrency, Jewellery, Renewable energy, Printed circuit board, Iron ore, Security (finance), Management, Uranium mining, Gold

The royalty interests consist of a gold royalty on the Serrote mine, a gold, platinum and palladium royalty on the Santa Rita mine, and a copper and nickel royalty on both the Serrote and Santa Rita mines (collectively, the “Royalties”).

Key Points: 
  • The royalty interests consist of a gold royalty on the Serrote mine, a gold, platinum and palladium royalty on the Santa Rita mine, and a copper and nickel royalty on both the Serrote and Santa Rita mines (collectively, the “Royalties”).
  • “I am pleased to announce this proposed acquisition of royalties on two attractive producing mines,” commented Bill Heissenbuttel, President and CEO of Royal Gold.
  • At the Santa Rita mine, an underground expansion project could provide a 27-year extension to the mine life.
  • The royalties will be effective as of May 1, 2023, and revenue to Royal Gold will be accrued from that date.